Company profile: Entasis Therapeutics
1.1 - Company Overview
Company description
- Provider of anti-infective therapies for serious drug-resistant bacterial infections. Products include GIAPREZA (angiotensin II to increase blood pressure in septic or distributive shock), XERAVA (eravacycline for complicated intra-abdominal infections), XACDURO (sulbactam/durlobactam for hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex), and zoliflodacin (Phase 3 for uncomplicated gonorrhea).
Products and services
- XACDURO: An injectable combination of sulbactam and durlobactam engineered to treat hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible Acinetobacter baumannii-calcoaceticus complex strains
- XERAVA: An adult-indicated antibiotic containing eravacycline, used for the treatment of complicated intra-abdominal infections in adult patients
- Zoliflodacin: A Phase 3 investigational antibiotic developed for the treatment of uncomplicated gonorrhea infection, currently undergoing Phase 3 clinical trials
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Entasis Therapeutics
Utility Therapeutics
HQ: United Kingdom
Website
- Description: Provider of antibiotics focused on combating multi-drug resistant bacterial infections in the US, including PIVYA (pivmecillinam, oral) for UTIs with a unique mode of action addressing resistance, and mecillinam (IV) targeting penicillin binding protein-2 in gram-negative bacteria and stable against β-lactamase hydrolysis, plus a development program working with the FDA to make PIVYA tablets available for uncomplicated UTIs in the US.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Utility Therapeutics company profile →
Durata Therapeutics
HQ: United States
Website
- Description: Provider of late-stage clinical development of novel antibiotics for infectious diseases, focused on Vicuron’s antibiotic.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Durata Therapeutics company profile →
Coris BioConcept
HQ: Belgium
Website
- Description: Provider of rapid diagnostic kits, developing, marketing and selling assays including RESIST Range for antibiotic resistance (carbapenemase-producing organisms), Legionella K-SeT lateral flow test for Legionella pneumophila, HAT Sero K-SeT for Trypanosoma brucei gambiense, BL-RED electrochemical test for bacterial hydrolysis related to 3GC antibiotics, Giardia-Strip dipstick test, and RT-LAMP fluorescence assays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Coris BioConcept company profile →
Cytophage
HQ: Canada
Website
- Description: Provider of bacteriophage development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cytophage company profile →
Pharmasset
HQ: United States
Website
- Description: Provider of novel oral therapeutics to treat viral infections, with a primary focus on hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency virus (HIV). Clinical-stage pharmaceutical company committed to discovering, developing, and commercializing antiviral drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pharmasset company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Entasis Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Entasis Therapeutics
2.2 - Growth funds investing in similar companies to Entasis Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Entasis Therapeutics
4.2 - Public trading comparable groups for Entasis Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →